Reduced activity of moxidectin and ivermectin on small strongyles in young horses on a farm (BC) in Central Kentucky in two field tests with notes on variable counts of eggs per gram of feces (EPGs).

Two field tests (A and B) were conducted in Thoroughbred weanlings born in 2008 and 2009 on a farm (BC) in Central Kentucky. The purpose was to determine the current efficacy of moxidectin (MOX) and ivermectin (IVM) on small strongyles by pre- and posttreatment counts of eggs per gram of feces (EPGs) in this geographical area. In previous parasite studies in horses on this farm and in horses on numerous other farms in this area, cultures of feces indicated the strongyle larvae were all small strongyles. Therefore, the strongyle eggs in the EPG counts are considered small strongyles. Designation of the location of the horses in the current study is by barn number. However, the horses were kept on pastures except when gotten up in the specific barns for treatment and collection of feces. The number of horses for study A (2008-2009) was 40 in a total of ten barns (four in each location) and that for study B (2009-2010) was 49 in a total of nine barns (four each in six locations and seven to nine each in three locations). The nine barns for the study-B horses were the same ones used for the study-A horses; the tenth barn for study A was not used for study B. The number of horses treated was 20 with MOX and 20 with IVM in study A and 24 with MOX and 25 with IVM in study B. Drugs given to horses in barns in study B were switched from those used in barns in study A. That is, horses in barns where MOX was used in study A were given IVM and vice versa for those in study B. Study-A horses in some of the barns had unexplained either negative or delayed return of EPG counts after treatment with either drug, compared to horses in other barns. No reason for inconsistencies could be determined. Study B was initiated to compare results with study-A horses, relative to their location in the same barns. Study- B horses, contrary to horses in study A, had mostly consistent results between barns. Most of the MOX- and IVM-treated horses in study B and some in study A had strongyle EPG counts returning almost twice as quickly as when these compounds were first marketed.